Novartis' heart failure medicine LCZ696 granted accelerated assessment by CHMP in Europe
Novartis announced the CHMP has granted accelerated assessment to LCZ696, an investigational medicine for patients with heart failure with reduced ejection fraction. The designation allows the CHMP to grant an opinion at day 150 versus a normal 210 day procedure. November 28, 2014